Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.40 |
| ▸ | STK10 | O94804 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | YES1 | P07947 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1850726 | 0.93 | PIK3CA (0.40) | PIK3CAERN1AXLPIK3R1MTOR | |
| SCHEMBL1848707 | 0.92 | PIK3CA (0.42) | PIK3CAAXLPIK3R1PIK3CDMTOR | |
| SCHEMBL574939 | 0.91 | BRAF (0.43) | PIK3CAERN1METAXLPLK4 | |
| SCHEMBL1846102 | 0.87 | ERN1 (0.40) | PIK3CAERN1MTOR | |
| SCHEMBL1851673 | 0.86 | PIK3CA (0.40) | PIK3CAERN1AXLPIK3CDMTOR | |
| SCHEMBL1847135 | 0.84 | ERN1 (0.39) | PIK3CAERN1MTOR | |
| SCHEMBL1845246 | 0.84 | MAPK13 (0.48) | PIK3CAERN1SRCMTOR | |
| SCHEMBL15192467 | 0.83 | BRAF (0.45) | PIK3CAAXLHTR1AHTR7 | |
| SCHEMBL1852276 | 0.82 | ERN1 (0.41) | PIK3CAERN1MTOR | |
| SCHEMBL574488 | 0.77 | BRAF (0.48) | PIK3CAERN1PIK3R1PIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-02 | — | — | US | claimed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | claimed |
| EP-2324008-B1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-05-09 | — | — | EP | claimed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | claimed |
| EP-2324008-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-25 | — | — | EP | claimed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | claimed |
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-02 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2324008-B1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-05-09 | — | — | EP | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| EP-2324008-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | PIK3CA 84/4885ERN1 702/4885MET 1322/4885 |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | PIK3CA 84/4885ERN1 702/4885MET 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.